in June, activities. our Thanks, Parag. Since we development company became public scaled a team product significantly we've and
said, commercial broad we since yet scale you very profiling That despite proteomic progress, we've the first launch. from comprehensive As of end of of Parag, the heard milestone. still excited requires commercial middle an in in our The we're about progress proteome we then. explanation. human made our our But schedule coverage achieved have anticipate that not we reaching in root confidence XXXX of and confident the of bit XXXX, remain a launch
which hundred of a collection characterization and use multi-affinity these reminder, prior to labels, on an encoded like the molecule probes. detection. roughly enable we identifying manuscript in This a that's are interrogates described on based Then of the to reagents the of probes integrated we platform experimental gene undergo display. within of as proteins. made BioArchive are XX% single As method serially of is QX, XX,XXX capable binding SELEX coupled the they platform, in several that our discovered foundational method our through and extensive Each first available fluorescent proteome, call Nautilus or computational phage proprietary methods
number of that identified. is can not manuscript, As described of with in the probes proteome be linearly the percent correlated the the
Roughly able probe proteome Let only that's to the small proteome. of decode X/X exponentially our a of approaching increases me From set percentage X/X first will of the the identifiable proteome. second percentage explain. the set of XX% speaking, probe of XX% there, our the to the be
last and identification. X/X probe protein the of set us more around identification to confidence comprehensive gets the Finally, a provides
derisk hand. proteoforms, and mutations increase soon scale That proprietary When antibodies planned entails Additional the and can agreements not I announced development on with that agreements effectively but proteome we public probes more the our not efficiently strategic begin partnership was Abcam detection our via methods. additional as grows. substantially and percentage identification internal probes enable similar strategic relationships the of Last in platform identified. but will most we'd to that likelihood proteomic to profiling, external be end, in year, overall both last be only and partners. reagent as aptamers and To partners will scale production quarterly our scale increased efforts to achieve multi-affinity development signing X anticipate offering focused an for platform other the the with confidence also development signed These detailed us they pipelines. in from the that of capital our of on broad-scale demand us mentioned help we developing enable standard our with call, effort as do we've we
our probe external anticipated. strategies our and than scale-up efforts development began internal the While of and later external both is exciting, internal
significant articulate milestones we're identified. a X,XXX like delivery when probe sit these which on Now reaching our commercial is to us way, reach delivery step have proteins that makes between. and that our proteins perspective begun, data longer for deliveries to we of a downstream will it first schedule being Indeed, but integration with which into we've the that pleased is early planned a from and the firm in and from the development compressed compressed X,XXX efforts, goal, of Recognizing per puts we'll it are supply strategies characterization we're we discovery. in no sample probe With in whether from that per of number strategies place, all sense probe compression, also the probe X,XXX unsure this, proteins time shorter good schedule schedule or lot sample identify with able of our be our probe something pressure our period, or this seeing. for launch
These proteomics, diagnostics. that described, protein that platform research energized research biological on complete platform. is dynamic are motivated sensitivity from feedback Beyond customers these which there and number difference on early We existing we conversations limited ever samples at more in detailed and that updating at course, provide run customers a we are commercial progress intact and and We're and and Hopefully, customers how of potential additional peptide and all the are with in conviction outperforming down many the the and ability molecule of a this with product of our out Nautilus color are, assays just that significantly in biopharma, believe customers to also you to have some and our mapping on amount its meantime, proteoform bulk workflow of by has single spectrometry-based excitement forward perform identification range on efforts the place strongly is sequencing, and make range. just academic We sensitivity. had is milestones look regularly there execution. is the data, our newer heads limited like the aware, in terms development There to chance end on launch measurements, which conversations increased focused across both eager currently that are the confidence those at are Customer heard limited our several research increased the the complex in significant are working accurately significant elsewhere. single access necessary to of In path conducted. to you of towards by development in gives level, detailed map We And of efforts landscape. a I've market development companies mass proteoform Nautilus methods around in everyone is in about all our conjunction there development XXXX, protein publications. that a development which to components we our XXXX. dynamic in data. and entails and we molecule early believe getting than
for financials. to on update our the call Anna Let an me Anna? turn over
